Equity Field Notes from temporal sources

[DanWebzster]

PRTO has a clear pathway to market for its lead asset.

FDA confirmed that its Ph3 study due to read out 3/19 plus prior trials would be sufficient for a BLA submission.

Cash runway extends late into 2019.

There is a risk of dilution before the Ph3 read-out. PRTO could tap its ATM with Cowen.

Also, the results of the Ph3 are far from certain.

The best opty that this equity could present would be a sell-off into tax loss selling season; but, that seems unlikely give the stock's performance so far in 2018.